Literature DB >> 3417846

Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease.

J L Codaccioni1, J Orgiazzi, P Blanc, M Pugeat, R Roulier, P Carayon.   

Abstract

Twenty-six patients with Graves' hyperthyroidism treated only with propranolol for 1-21 months have been followed up to 5 years. The patients were evaluated before treatment, at 15, 30, and 90 days during treatment, and then at 90-day intervals during propranolol treatment by clinical examination and measurement of serum free T3, free T4, rT3, TSH, and sex hormone-binding globulin concentrations and serum anti-thyroglobulin, antithyroid microsomal, antithyroid peroxidase, and thyroid-stimulating autoantibodies. Eighteen patients who had no biochemical improvement during propranolol therapy or relapsed after initial improvement were treated conventionally. In contrast, eight patients had a biochemical remission, which has lasted 30-48 months after propranolol withdrawal. The biochemical values before and during treatment did not differ among the two groups of patients, except for the initial serum free T3 levels which were significantly higher in the patients who had no remission. Serum TSH levels returned to normal only in patients who had a long-lasting remission. While thyroid autoantibodies decreased or disappeared during follow-up, the evolution of thyroid-stimulating autoantibody values was grossly related to the clinical outcome. Long-lasting remissions may occur in patients with hyperthyroidism due to Graves' disease not given ablative or antithyroid drug therapy. Since propranolol is devoid of antithyroid and immunosuppressive actions, these remissions are probably spontaneous. Although they tended to occur in patients with less severe disease, no biological parameter was found that predicted the outcome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3417846     DOI: 10.1210/jcem-67-4-656

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  The inhibitory effect of large doses of methimazole on iodine induced lymphocytic thyroiditis and serum anti-thyroglobulin antibody titers in BB/Wor rats.

Authors:  W Reinhardt; M C Appel; S Alex; Y N Yang; L E Braverman
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

2.  Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.

Authors:  Ricardo V García-Mayor; Paula Álvarez-Vázquez; Enrique Fluiters; Diana Valverde; Amalia Andrade
Journal:  Endocrine       Date:  2018-10-17       Impact factor: 3.633

Review 3.  Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence.

Authors:  Jia Liu; Jing Fu; Yuan Xu; Guang Wang
Journal:  Int J Endocrinol       Date:  2017-04-25       Impact factor: 3.257

4.  Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling.

Authors:  Mariam Kourime; Sheena McGowan; Mabrouka Al Towati; S Faisal Ahmed; Graham Stewart; Scott Williamson; Iain Hunter; Malcolm D C Donaldson
Journal:  Arch Dis Child       Date:  2017-12-21       Impact factor: 3.791

5.  Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study.

Authors:  Simon H S Pearce; Colin Dayan; David C Wraith; Kevin Barrell; Natalie Olive; Lotta Jansson; Terrie Walker-Smith; Christina Carnegie; Keith F Martin; Kristien Boelaert; Jackie Gilbert; Claire E Higham; Ilaria Muller; Robert D Murray; Petros Perros; Salman Razvi; Bijay Vaidya; Florian Wernig; George J Kahaly
Journal:  Thyroid       Date:  2019-06-13       Impact factor: 6.568

6.  Long-term monitoring of Graves’ disease in children and adolescents: a single-centerzzm321990experience

Authors:  Selma Tunç; Özge Köprülü; Hatice Ortaç; Özlem Nalbantoğlu; Ceyhun Dizdarer; Korcan Demir; Behzat Özkan
Journal:  Turk J Med Sci       Date:  2019-04-18       Impact factor: 0.973

7.  The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.

Authors:  Ya Fang; Wen-Hua Du; Cao-Xu Zhang; Shuang-Xia Zhao; Huai-Dong Song; Guan-Qi Gao; Mei Dong
Journal:  BMC Endocr Disord       Date:  2021-11-30       Impact factor: 2.763

8.  Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study.

Authors:  Peter Laurberg; Birte Nygaard; Stig Andersen; Allan Carlé; Jesper Karmisholt; Anne Krejbjerg; Inge Bülow Pedersen; Stine Linding Andersen
Journal:  J Thyroid Res       Date:  2014-02-18

Review 9.  Concurrent Graves' Disease and TSH Secreting Pituitary Adenoma Presenting Suppressed Thyrotropin Levels: A Case Report and Review of the Literature.

Authors:  Jinrong Fu; Anhua Wu; Xiaoli Wang; Haixia Guan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-06       Impact factor: 5.555

10.  Antithyroid Drug Treatment in Graves' Disease.

Authors:  Jae Hoon Chung
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.